Table 2.

Cox proportional hazard ratio and 95% confidence interval, time from diagnosis to death by biomarker status for all pancreatic tumors in the TMA

FamilyMarkerSignalNo *Median survival Unadjusted HR (95% CI)Adjusted HR (95% CI)
MucinsMUC1Positive14362.6(1.5-4.5)1.7(1.0-3.1)
Negative18271.0Reference1.0Reference
MUC2Positive8951.5(1.1-2.1)1.4(1.0-2.1)
Negative72111.0Reference1.0Reference
MUC5ACPositive9951.3(0.9-1.8)1.4(1.0-2.0)
Negative629.51.0Reference1.0Reference
Neuro- endocrine markersSynaptophysinModerate/marked5580.9(0.6-1.3)1.0(0.7-1.4)
None/weak10161.0Reference1.0Reference
ChromograninModerate/marked24130.6(0.4-0.9)0.9(0.6-1.5)
None/weak13061.0Reference1.0Reference
Neuron-specific enolaseModerate/marked5251.3(0.9-1.9)1.1(0.8-1.7)
None/weak99101.0Reference1.0Reference
Growth factor receptorsEGFRModerate/marked4051.2(0.8-1.8)1.2(0.8-1.8)
None/weak1149.51.0Reference1.0Reference
HER2Moderate/marked966.51.2(0.9-1.7)0.9(0.6-1.3)
None/weak5781.0Reference1.0Reference
T cell markerCD5Moderate/marked2590.9(0.6-1.4)0.9(0.5-1.3)
None/weak13171.0Reference1.0Reference
CD138Moderate/marked10961.1(0.8-1.6)1.1(0.7-1.5)
None/weak47101.0Reference1.0Reference
CytokeratinsCK20Moderate/marked706.51.0(0.7-1.5)1.1(0.8-1.6)
None/weak769.51.0Reference1.0Reference
CK5/6Moderate/marked7490.8(0.5-1.0)0.9(0.6-1.2)
None/weak8061.0Reference1.0Reference
CK19Moderate/marked13961.2(0.8-2.0)1.3(0.8-2.1)
None/weak228.51.0Reference1.0Reference
Tumor proteinp53Moderate/strong11961.2(0.8-1.8)1.0(0.6-1.5)
Negative/weak3181.0Reference1.0Reference
  • Abbreviation: HR, hazard ratio, CI, confidence interval; NSE, Neuron-specific enolase.

  • * Number of cases with data available varied by marker.

  • Survival time in months from diagnosis to death.

  • Adjusted for gender, age (<75 versus 75+ y), race (Asian versus non-Asian), stage of disease (local and regional versus distant and unstaged), pancreatic origin versus metastatic site, and ever versus never surgical or radiation treatment for pancreatic cancer.